Showing Results for
From:PLoS ONE (Vol. 16, Issue 9) Peer-ReviewedBackground In the United States, both cannabis use disorder (CUD) and opioid use disorder (OUD) have increased in prevalence. The prevalence, demographics, and costs of CUD and OUD are not well known in heart failure...
From:Mayo Clinic Proceedings (Vol. 96, Issue 6) Peer-ReviewedAbstract In 2013, the Food and Drug Administration approved the first transcatheter mitral valve repair (TMVr) device for degenerative mitral regurgitation for patients at prohibitive surgical risk. To better...
From:PLoS ONE (Vol. 16, Issue 3) Peer-ReviewedBackground Patients with restrictive or hypertrophic cardiomyopathy (RCM/HCM) and congenital heart disease (CHD) do not derive clinical benefit from inotropes and mechanical circulatory support. Concerns were...
From:PLoS ONE (Vol. 15, Issue 9) Peer-ReviewedBackground Patients with comorbid conditions have a higher risk of mortality with SARS-CoV-2 (COVID-19) infection, but the impact on heart failure patients living near a disease hotspot is unknown. Therefore, we...
Choose how you want to be alerted when new results for your search become available.
Subscribe to Gale's RSS feed to get content delivered to your favorite RSS aggregator. Copy and paste the URL below into your reader:
Tell us where to send the alert and how often you want to receive it